Seres Therapeutics
MCRB
85 hedge funds and large institutions have $326M invested in Seres Therapeutics in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 12 closing their positions.
53% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $698K
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
6% more funds holding
Funds holding: 80 → 85 (+5)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0.16% more ownership
Funds ownership: 3.8% → 3.96% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
34% less capital invested
Capital invested by funds: $494M → $326M (-$168M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.53M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.37M |
| 3 |
Renaissance Technologies
New York
|
+$3.06M |
| 4 |
Jennison Associates
New York
|
+$2.34M |
| 5 |
JP Morgan Chase
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$4.18M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.34M |
| 3 |
AG
Artal Group
Luxembourg
|
-$2.57M |
| 4 |
PA
Perceptive Advisors
New York
|
-$2.17M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.73M |
MCRB Hedge Fund Activity: Q4 2017 in Review
85 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2017, worth a combined $326M — down 34% from $494M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MCRB positions and 12 closed out — a net gain of 5 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $7.53M. The largest seller was Capital World Investors, cutting an estimated $4.18M.
- 85 institutional investors held Seres Therapeutics (MCRB) as of Q4 2017, up from 80 in Q3 2017.
- Funds reported $326M of Seres Therapeutics stock for Q4 2017, down 34% quarter-over-quarter.
- 17 funds opened new Seres Therapeutics positions in Q4 2017 and 12 closed out, a net change of +5 holders.
- The largest Seres Therapeutics buyer in Q4 2017 was ARK Investment Management, an estimated $7.53M added.
- The largest Seres Therapeutics seller in Q4 2017 was Capital World Investors, an estimated $4.18M sold.
Based on aggregated 13F filings for Q4 2017.